Milnocor (Milrinone)

Milrinone, the active ingredient in Milnocor, is a phosphodiesterase 3 inhibitor presented as an intravenous solution for intravenous use. It is employed to manage acute decompensated heart failure and cardiogenic shock in hospitalized patients, providing inotropic support and vasodilation to improve cardiac output. GNH USA supplies Milnocor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Milrinone acts as a cardiac inotropic and vasodilator in severe heart failure syndromes. - Acute decompensated heart failure: increases cardiac output and reduces pulmonary congestion. - Cardiogenic shock: provides rapid inotropic support to maintain systemic perfusion. - Post‑cardiac surgery low cardiac output: improves myocardial performance during the immediate postoperative period.

Milrinone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: reduction in systemic blood pressure. - Tachyarrhythmias: accelerated heart rhythm including atrial fibrillation. - Headache: mild to moderate discomfort. - Nausea: gastrointestinal upset.

Serious or Rare Side Effects: - Ventricular tachycardia or fibrillation: life‑threatening arrhythmias. - Severe hypotension: marked drop in blood pressure requiring intervention. - Myocardial ischemia: reduced coronary perfusion. - Allergic reactions: rash, bronchospasm, or anaphylaxis.

Milrinone requires careful clinical monitoring due to its potent cardiovascular effects. - Cardiac monitoring: continuous ECG and hemodynamic assessment are essential. - Electrolyte balance: correct potassium and magnesium levels to reduce arrhythmia risk. - Renal function: adjust dosing in patients with impaired clearance. - Concomitant vasodilators: avoid or use with caution to prevent excessive hypotension. - Contraindications: do not use in patients with obstructive hypertrophic cardiomyopathy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma milrinone concentrations. - Potent vasodilators (e.g., nitroprusside): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the inotropic response, requiring hemodynamic monitoring. - Diuretics: electrolyte shifts can predispose to arrhythmias; monitor serum levels. - ACE inhibitors or ARBs: additive blood‑pressure lowering effects, observe for hypotension.